A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

Omitting biopsy in patients with a negative prostate MRI more than halves the diagnoses of clinically insignificant prostate cancer. Detection of clinically insignificant ISUP grade group 1 prostate ...

What key experiences or clinical gaps motivated your focus on advancing prostate cancer diagnostics, particularly MRI-led ...

Excluding systematic biopsy in favor of MRI-targeted biopsy in men with elevated prostate-specific antigen (PSA) levels reduced the probability of detecting clinically insignificant cancers, but at ...

Prostate MRI currently lacks the accuracy to replace biopsies in active surveillance for prostate cancer. The negative predictive value of MRI remains below 90%, the general goal for safely avoiding ...

There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next ...

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...

Compared with systematic biopsy, MRI-directed targeted biopsy reduces the risk of overdiagnosis of prostate cancer for men with elevated prostate-specific antigen levels, according to researchers.